September oncology coverage highlighted new breast and kidney cancer combinations, updated lung cancer labeling, and emerging evidence connecting antibiotic exposure with CAR T-cell outcomes.
|Articles|October 27, 2021
Pharmacy Clinical Pearl of the Day: Breast Cancer
Author(s)Saro Arakelians, PharmD
After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States.
Advertisement
Clinical Pearl of the Day: Breast Cancer
Breast cancer is a cancer that forms in the cells of the breasts.
Insight:
- After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States.
- Breast cancer can occur in both men and women, but it's far more common in women.
- Symptoms include a breast lump or thickening that feels different; change in the size, shape, or appearance of the breast; a newly inverted nipple; peeling, scaling, crusting or flaking of the pigmented area of skin; and redness or pitting of the skin.
- Risk factors include being female, increasing age, history of breast cancer, family history, obesity, and having a child at an older age.
- Diagnostic tools may include breast exam, mammogram, breast ultrasound, biopsy, and MRI.
- Treatment includes lumpectomy, mastectomy, sentinel node biopsy, axillary lymph node dissection, radiation therapy, chemotherapy, hormone therapy, targeted drug therapy, immunotherapy, and palliative care.
- Chemotherapy can be given before surgery (neoadjuvant) or after surgery (adjuvant).
- Adjuvant and neo-adjuvant drug may include anthracyclines, such as doxorubicin (Adriamycin), epirubicin (Ellence); taxanes such as paclitaxel (Taxol) and docetaxel (Taxotere), 5-Fluorouracil (5-FU) or capecitabine, cyclophosphamide (Cytoxan), and carboplatin.
Sources:
Advertisement
Related to this article
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
IRAKLIA data show that isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion rates.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
2
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
3
Expert Q&A: Researcher Urges Autonomic Assessment for Patients With Long COVID
4
Sotatercept in ERS PAH Guidelines: What Pharmacists Should Watch
5